Evidence & regulatory context
- Mechanism
- No ChEMBL entry returned for 'carnosic acid' (explicit zero result). No ClinicalTrials.gov study identified with carnosic acid as a named intervention; a rosemary-extract keyword search returned only unrelated records, all rejected.
- Target
- Not recorded
- Injury models
- TBI
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseTBIControlled cortical impactCF-1Malen = 8 to 10 per group for dose response and therapeutic window;…Intraperitoneal0.3, 1.0 or 3.0 mg/kg, injection volume not exceeding 0.3 ml15 minutes after injury; therapeutic window study used first dose at 15 minutes…
Model: Controlled cortical impact with 1.0 mm cortical deformation
Carnosic acid given 15 minutes after injury reduced cortical lipid peroxidation, protein nitration and cytoskeletal breakdown in a dose-dependent U-shaped manner at 48 hours, with 1.0 mg/kg most consistently effective and preserving mitochondrial complex I and II respiration at 24 hours. Delaying t…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.